Renal ImpairmentPhase 1NCT05844228

A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218

A Phase 1 study testing VIR-2218 in people with Renal Impairment, run by Vir Biotechnology, Inc. at 3 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The rationale of this study is to evaluate the impact of renal function on the PK, safety, and tolerability of VIR-2218 in participants with normal renal function and participants with varying degrees of renal dysfunction who are otherwise medically stable Read more about this study

Who is it for?: Ages 18 to 80 yearsHealthy volunteers can take part
Conditions the study is for: Renal Impairment
What is being tested?: VIR-2218
Type of treatment: Injection or infusion
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 28 participants
Where: 3 sitesUnited States
Study dates: 1 Jun 2023to 21 Apr 2025
Phase: Phase 1
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 80 years
All sexes
Healthy volunteers accepted
Adult, Older adult

Who may be able to join

Participants must have stable renal function as defined by less than 20% change in estimated glomerular filtration rate (eGFR) between the first and second screening sample with the first screening visit occurring within 28 days prior to dosing on Day 1 and the second screening visit occurring no more than 14 days apart, but at least 72 hours apart from the first.
Body mass index (BMI) within the range 18.5 to 40.0 kg/m^2 at screening.
Female and Male participants must consent to follow contraception requirements
Capability of giving signed informed consent form
Inclusion Criteria: Additional Criteria Specific to Healthy Participants:
Must be in the opinion of the investigator, be in good health based upon medical history, vital signs, physical examination, and screening laboratory evaluations

Show all 12Show fewer

Must have normal renal function as defined by eGFR ≥ 90 mL/min/1.73m^2 based on the Modification of Diet in Renal Disease (MDRD) equation determined from the mean of two measurements of serum creatinine at screening.
Inclusion Criteria: Additional Criteria Specific to Participants with Renal Impairment
Participants must, in the opinion of the investigator, be sufficiently healthy for study participation based on medical history, physical examination, vital signs, and screening laboratory evaluations
Participants with RI must have chronic moderate or severe RI and be clinically stable per investigator assessment for at least 3 months prior to screening
Moderate RI as defined by eGFR level 30-59 mL/min/1.73m^2 based on the MDRD equation, or
Severe RI as defined by eGFR level 15-29mL/min/1.73m^2 based on the MDRD equation

Who cannot join

Any clinically significant medical condition or psychiatric condition that may interfere with study intervention
Participants with uncontrolled hypertension, asthma, and/or diabetes (Type I or II).
Participants with diabetes
Participants with any active malignancy
Participants with vasculitis or conditions associated with vasculitis.
Participants who have undergone major surgery within 12 months of screening

Show all 19Show fewer

Participants with unstable cardiac functions, abnormality, or clinically significant heart failure
Participants with infection of HIV, HAV, HBV, HCV, HDV, or HEV
Participants with signs of active infection
History of bone marrow or solid organ transplantation
Participants with end-stage renal disease or nephrotic syndrome as defined by: participants requiring hemodialysis or peritoneal dialysis, participants who have undergone or are listed for transplant, or participants who have chronic kidney disease with nephrotic syndrome
Participants with active nephritis
Participants with clinically significant liver disease
History of drug or alcohol abuse
Unwillingness or inability to follow procedures outlined in protocol
Exclusion Criteria: Additional Criteria Specific to Healthy Participants
Use of any prescription medications or over-the-counter medications (with the exception of vitamins and/or hormonal contraceptive medications) including herbal products within 30 days prior to D1 of study participation
Exclusion Criteria: Additional Criteria Specific to Participants with Renal Impairment
Not on stable dose and regimen of any medication(s) (prescription or over-the-counter) that the participants is taking regularly (eg, medications for chronic conditions such as hypertension, high cholesterol, or depression must not be changed in dose or type for at least 2 weeks prior to study drug administration). Use of other prescription medications or over-the-counter medications that are not for chronic conditions (with the exception of vitamins and/or hormonal contraceptive medications) including herbal products within 30 days prior to D1 of study participation

Trial locations and contacts

3 sites in 1 country.

United States3 sites

Floridian Clinical Research
Miami Lakes, Florida, 33016
Orlando Clinical Research Center
Orlando, Florida, 32809
Inland Empire Clinical Trials
Rialto, California, 92377

Other trials in United States

About this study

Official title: A Phase 1, Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of VIR-2218 in Adult Participants With Renal Impairment

Read the detailed description

Participants may be enrolled in Cohorts 1 and 2 in a non-randomized way.

Conditions: Renal Impairment
Being tested: VIR-2218
Medical subject headings: Renal Insufficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

VIR-2218Drug
Also called Elebsiran
VIR-2218 given by subcutaneous injection

Study groups in NCT05844228
Study group	Role	What they receive
Cohort 1: Up to 8 moderate Renal Impairment participants and up to 8 matched healthy participants	Experimental	Not described Receives: Drug: VIR-2218
Cohort 2: Up to 8 severe Renal Impairment participants and up to 8 matched healthy participants	Experimental	Not described Receives: Drug: VIR-2218

What is being measured

The primary outcome is the main question the study is designed to answer.

Maximum Observed Plasma Concentration (Cmax) of VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218
Pharmacokinetic samples were collected at -2 hours pre-dose and at 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, and 96 hours post-dose.
Measured: 4 days
Area Under The Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218
Pharmacokinetic samples were collected at -2 hours pre-dose and at 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, and 96 hours post-dose.
Measured: 4 days
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218
Pharmacokinetic samples were collected at -2 hours pre-dose and at 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, and 96 hours post-dose.
Measured: 4 days
Fraction Excreted in Urine in Percentage for VIR-2218
Measured: 4 days
Amount Excreted in Urine for VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218
Measured: 4 days
Renal Clearance for VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218
Measured: 4 days

Secondary outcomes (1)

Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Measured: 8 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1 Jun 202321 Apr 2025

First posted6 May 2023
Study start1 Jun 2023
Primary completion1 Mar 2025
Study completion21 Apr 2025

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for Renal ImpairmentStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 1
Primary purpose: Treatment
Allocation: Non-randomised
Intervention model: Parallel groups
Masking: None (open label)
Enrolment: 28 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05844228
Sponsor's protocol ID: VIR-2218-V108
Status last verified: Oct 2026
First submitted: 24 Apr 2023
Last updated: 16 Oct 2026
Results posted: Yes, on ClinicalTrials.gov
FDA-regulated drug: Yes
FDA-regulated device: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
RecruitingPhase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Berger Disease, Bergers Disease
Recruiting
NightWare and Cardiovascular Health in Women With PTSD
Post Traumatic Stress Disorder, Cardiovascular Diseases
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant

All Renal Impairment trials

Study at a glance

From the registry record, last updated by the sponsor on 16 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Phase 1, Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of VIR-2218 in Adult Participants With Renal Impairment
ClinicalTrials.gov ID: NCT05844228
Acronym / sponsor ID: VIR-2218-V108
Conditions: Renal Impairment
Phase: Phase 1
Study type: Interventional
Recruitment status: Completed
Enrolment: 28 participants (actual)
Lead sponsor: Vir Biotechnology, Inc.Industry (pharma, biotech, devices)
Study start: 1 Jun 2023 (actual)
Primary completion: 1 Mar 2025 (actual)
Study completion: 21 Apr 2025 (actual)
First posted: 6 May 2023 (actual)
Results: Posted 16 Oct 2026

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Participants may be enrolled in Cohorts 1 and 2 in a non-randomized way.

Study design

Primary purpose: Treatment
Allocation: Non-randomised
Intervention model: Parallel groups
Masking: None (open label)
Number of arms: 2

Arm	Type	Receives
Cohort 1: Up to 8 moderate Renal Impairment participants and up to 8 matched healthy participants	Experimental	Drug: VIR-2218
Cohort 2: Up to 8 severe Renal Impairment participants and up to 8 matched healthy participants	Experimental	Drug: VIR-2218

Who may qualify

Ages: 18 to 80 years
Sex: All
Healthy volunteers: Accepted
Age groups: Adult, Older adult

Key inclusion criteria (12 listed)

Participants must have stable renal function as defined by less than 20% change in estimated glomerular filtration rate (eGFR) between the first and second screening sample with the first screening visit occurring within 28 days prior to dosing on Day 1 and the second screening visit occurring no more than 14 days apart, but at least 72 hours apart from the first.
Body mass index (BMI) within the range 18.5 to 40.0 kg/m^2 at screening.
Female and Male participants must consent to follow contraception requirements
Capability of giving signed informed consent form
Must be in the opinion of the investigator, be in good health based upon medical history, vital signs, physical examination, and screening laboratory evaluations

Key exclusion criteria (19 listed)

Any clinically significant medical condition or psychiatric condition that may interfere with study intervention
Participants with uncontrolled hypertension, asthma, and/or diabetes (Type I or II).
Participants with diabetes
Participants with any active malignancy
Participants with vasculitis or conditions associated with vasculitis.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
VIR-2218Also: ElebsiranVIR-2218 given by subcutaneous injection	Drug	Cohort 1: Up to 8 moderate Renal Impairment participants and up to 8 matched healthy participants, Cohort 2: Up to 8 severe Renal Impairment participants and up to 8 matched healthy participants

Primary outcome

Maximum Observed Plasma Concentration (Cmax) of VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218
Time frame: 4 days
Pharmacokinetic samples were collected at -2 hours pre-dose and at 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, and 96 hours post-dose.
Area Under The Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218
Time frame: 4 days
Pharmacokinetic samples were collected at -2 hours pre-dose and at 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, and 96 hours post-dose.
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218
Time frame: 4 days
Pharmacokinetic samples were collected at -2 hours pre-dose and at 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, and 96 hours post-dose.
Fraction Excreted in Urine in Percentage for VIR-2218
Time frame: 4 days
Amount Excreted in Urine for VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218
Time frame: 4 days
Renal Clearance for VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218
Time frame: 4 days

1 secondary outcome

Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: 8 weeks

Results and safety

Results posted to the registry on 16 Oct 2026, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Cohort 1: Single Dose of VIR-2218 in Moderate Renal Impairment and Matched Healthy Participants	16	16
Cohort 2: Singe Dose of VIR-2218 in Severe Renal Impairment and Matched Healthy Participants	12	12

Primary outcome: Maximum Observed Plasma Concentration (Cmax) of VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218

Time frame: 4 days. Geometric mean (Geometric Coefficient of Variation). Unit: ng/mL

Measure	Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment Participants n = 8	Cohort 1: Singe Dose of VIR-2218 in 8 Healthy Matched Participants n = 8	Cohort 2: Singe Dose of VIR-2218 in up to 8 Severe Renal Impairment Participants n = 6	Cohort 2: Singe Dose of VIR-2218 in up to 8 Healthy Matched Participants n = 6
VIR-2218 Cmax	319 (31.4)	390 (13.2)	584 (32.6)	488 (19.9)
AS(N-1)3'VIR-2218 Cmax	44.7 (42.4)	49.5 (31.6)	91.7 (52.3)	59.3 (33.6)

Primary outcome: Area Under The Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218

Time frame: 4 days. Geometric mean (Geometric Coefficient of Variation). Unit: h*ng/mL

Measure	Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment Participants n = 8	Cohort 1: Singe Dose of VIR-2218 in 8 Healthy Matched Participants n = 8	Cohort 2: Singe Dose of VIR-2218 in up to 8 Severe Renal Impairment Participants n = 6	Cohort 2: Singe Dose of VIR-2218 in up to 8 Healthy Matched Participants n = 6
VIR-2218 AUClast	7140 (28.1)	6590 (24.4)	11100 (47.3)	8240 (19.0)
AS(N-1)3'VIR-2218 AUClast	1050 (34.2)	812 (39.4)	2020 (49.3)	1080 (20.9)

Primary outcome: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218

Time frame: 4 days. Geometric mean (Geometric Coefficient of Variation). Unit: h*ng/mL

Measure	Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment Participants n = 8	Cohort 1: Singe Dose of VIR-2218 in 8 Healthy Matched Participants n = 8	Cohort 2: Singe Dose of VIR-2218 in up to 8 Severe Renal Impairment Participants n = 6	Cohort 2: Singe Dose of VIR-2218 in up to 8 Healthy Matched Participants n = 6
VIR-2218 AUCinf	7550 (31.7)	6670 (30.3)	11300 (47.2)	8530 (19.0)
AS(N-1)3'VIR-2218 AUCinf	1240 (35.3)	1110 (46.0)	2740 (36.2)	1220 (29.0)

Primary outcome: Fraction Excreted in Urine in Percentage for VIR-2218

Time frame: 4 days. Geometric mean (Geometric Coefficient of Variation). Unit: fe%

Measure	Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment Participants n = 8	Cohort 1: Singe Dose of VIR-2218 in 8 Healthy Matched Participants n = 8	Cohort 2: Singe Dose of VIR-2218 in up to 8 Severe Renal Impairment Participants n = 6	Cohort 2: Singe Dose of VIR-2218 in up to 8 Healthy Matched Participants n = 6
Value	9.18 (35.8)	12.6 (36.6)	4.96 (50.7)	15.9 (30.1)

1 secondary outcome is reported in the full results.

Adverse events

Time frame: Up to 12 weeks. Other adverse events reported at 1.25% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment Participants	0 of 8 (0%)	2 of 8 (25%)	0 of 8
Cohort 1: Singe Dose of VIR-2218 in 8 Healthy Matched Participants	0 of 8 (0%)	0 of 8 (0%)	0 of 8
Cohort 2: Singe Dose of VIR-2218 in 6 Severe Renal Impairment Participants	0 of 6 (0%)	5 of 6 (83.3%)	0 of 6
Cohort 2: Singe Dose of VIR-2218 in 6 Healthy Matched Participants	0 of 6 (0%)	2 of 6 (33.3%)	0 of 6

Limitations and caveats (from the sponsor): In Cohort 1, there was one race mismatch between a patient with moderate RI (White) and their matched healthy counterpart (Black). An ad hoc analysis was performed to compare the resulting PK parameters with or without the mismatched pair.

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.

Related trials for Renal Impairment

Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
RecruitingPhase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Berger Disease, Bergers Disease
Recruiting
NightWare and Cardiovascular Health in Women With PTSD
Post Traumatic Stress Disorder, Cardiovascular Diseases
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

3 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing VIR-2218 in people with Renal Impairment, run by Vir Biotechnology, Inc. at 3 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 16 Oct 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Maximum Observed Plasma Concentration (Cmax) of VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218 (time frame: 4 days). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05844228.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026.